This page contains brief information about polatuzumab vedotin-piiq and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Polatuzumab vedotin-piiq is approved to treat:
- Diffuse large B-cell lymphoma in adults whose cancer has relapsed or has not gotten better after at least two other therapies. It is used with bendamustine hydrochloride and rituximab.
This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that polatuzumab vedotin-piiq provides a clinical benefit in these patients.
Polatuzumab vedotin-piiq is also being studied in the treatment of other types of cancer.
More About Polatuzumab Vedotin-piiq
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Polatuzumab Vedotin-piiq - Check for trials from NCI's list of cancer clinical trials now accepting patients.